Secukinumab is the first human monoclonal antibody among antibody drugs targeting IL-17 that has been approved for clinical use, and has shown positive effects in psoriasis, psoriatic arthritis, and ankylosing spondylitis [22,116,117,118,119]. Here, IL17A is linked to psoriasis.